CLN3-Associated NCL Case with a Preliminary Diagnosis of Niemann Pick Type C

• Published in: Molecular syndromology Vol. 14; no. 1; pp. 30 - 34
• Main Authors: Kasapkara, Çiğdem Seher, Ceylan, Ahmet Cevdet, Yılmaz, Deniz, Kıreker Köylü, Oya, Yürek, Burak, Civelek Ürey, Burcu, Gündüz, Mehmet
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.02.2023
• Subjects: Novel Insights from Clinical Practice; CLN3; LysoSM-509; Juvenile neuronal ceroid lipofuscinosis
• ISSN: 1661-8769; 1661-8777
• DOI: 10.1159/000525100

Introduction: Neuronal ceroid lipofuscinoses (NCLs) are a broad class of inherited lysosomal storage disorders. Known mutations in at least 13 different genes can result in NCL with variable ages of onset, symptoms, and pathologic findings. Generally, these patients experience cognitive and motor decline, seizures, visual impairment, and premature death. Pathologically, NCL patients display heterogeneous histologic abnormalities, but consistently exhibit neuronal loss, reactive gliosis, and lysosomal accumulation of autofluorescent storage material or lipopigment. Juvenile-onset NCL has been classically referred to as Batten disease. By far the most prevalent NCL is CLN3-associated disease. It is an autosomal recessive condition that is usually caused by mutations in the ceroid-lipofuscinosis, neuronal 3 (CLN3) gene. CLN3 encodes battenin, a ubiquitously expressed transmembrane protein of unknown function that is associated with cellular homeostasis and neuronal survival. The initial clinical symptom of CLN3-associated NCL is central vision loss, which is usually detected between 4 and 9 years of age. Seizures typically begin early in the second decade of life, and affected individuals rarely live beyond their mid-20ies. Case Presentation: Herein, we describe a 16-year-old patient with CLN3-related juvenile NCL with a preliminary diagnosis of Niemann Pick Type C disease. The proband showed characteristic clinical signs, including epilepsy, ataxia, psychomotor regression, dementia, and visual impairment with an unusual elevation of lyso-sphingomyelin-509 (Lyso­SM-509; 812 nmol/L, normal 1–33 nmol/L). A homozygous NM_001042432.2(CLN3):c.233dup (p.Thr80fs) variant was detected at exon 4 of CLN3. Diagnosis of NCL was difficult due to the pronounced elevation of LysoSM-509. Discussion: LysoSM-509 is a biomarker which is elevated especially in Niemann Pick Type C. We can consider that a high LysoSM-509 level might be also an indicator of NCL, especially NCL type 3.